News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galapagos NV (GLPG.BR) To Present Favorable Pre-Clinical Data On GLPG1790, A Selective Ephrin Receptor Kinase Inhibitor, At American Association for Cancer Research In San Diego


3/18/2014 9:17:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MECHELEN, Belgium, March 18, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) will present favorable pre-clinical data on GLPG1790 in triple-negative breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on 7 April 2014. In the abstract, Galapagos disclosed that GLPG1790 is the first selective small molecule inhibitor of the ephrin receptor kinase family, which could play a key role in melanoma, pancreatic, ovarian, prostatic, and colorectal cancers, in addition to triple-negative breast cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES